Provider of next-generation POCT platform designed to diagnose infectious diseases. The company's platform is developing a consumer-oriented point-of-care blood testing device based on a nanotechnology biosensing method that can deliver results in a few minutes with a single drop of blood, enabling people to monitor, control and manage virus outbreaks better.

The firm's innovative dengue/COVID-19 rapid diagnostic tool is specifically designed for use in emerging markets and provides a climate adaptive product that helps equip affected populations with the required instruments to adjust to more frequent incidences of vector borne diseases.